Ulocuplumab (Anti-CXCR4 / CD184)

Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD.
Supplier Selleck Chemicals
Product # A2523
Sku # A2523-1mg*5
Pricing 1mg*5, $790.00
Feedback